Apixaban

Patient

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

Safety note. Ask your team before stopping. Stopping early can raise clot risk. A spine procedure can cause bleeding near the spine and lasting paralysis. Do not take apixaban during active pathological bleeding or after a severe allergy to Eliquis or its ingredients. FDA26

patient-07 — How much is usually taken, and how often?

Established. The dose depends on why apixaban was prescribed. For atrial fibrillation, many adults take 5 mg twice a day. Some take 2.5 mg twice a day when at least two factors apply: age 80 or older, weight 60 kg or less, or a blood creatinine result of 1.5 mg/dL or higher. Clot treatment and surgery prevention use different plans. Check your own label and ask your pharmacist why your dose was chosen. Do not change it yourself.

Sources: FDA26

patient-10 — What if I accidentally take too much?

Established. Taking extra apixaban can cause serious bleeding. Get urgent medical advice or contact Poison Help at 1-800-222-1222, even if you feel well. Do not try to make yourself vomit or take another medicine to reverse it. Emergency teams decide what care is needed. The current FDA label has mixed wording about reversal medicines, and Andexxa sales ended in the United States in December 2025. Tell the team how much was taken and when, and bring the medicine package if you can.

Sources: FDA26; FDA-AND

patient-15 — Can it interact with medicines or supplements?

Established. Yes. Some medicines can raise apixaban levels and bleeding risk. Others can lower its effect and raise clot risk. Examples include certain antifungal drugs, ritonavir, rifampin, carbamazepine, phenytoin, and St. John’s wort. Aspirin, ibuprofen, naproxen, and other blood thinners can add bleeding risk. Give your pharmacist a full list, including vitamins and herbs, before starting something new. Do not stop apixaban or change a dose on your own.

Sources: FDA26

patient-18 — Will I need tests or monitoring?

Established. There is no routine INR test that tells how strong apixaban is, as there is for warfarin. The test results can change a little, but they do not measure its effect well. Your clinician may still check kidney and liver health, blood counts, bleeding symptoms, and other medicines. These checks help confirm that the treatment remains suitable. Keep appointments and ask what each test is checking. Do not skip follow-up just because you feel well or because an INR result looks normal.

Sources: FDA26; DOAC26

patient-20 — What if it is not helping?

Established. Apixaban lowers the chance of certain clots; it may not make you feel different. Feeling well does not show that the medicine is no longer needed. If you have new chest pain, trouble breathing, one-sided weakness, a sudden severe headache, or heavy bleeding, seek emergency care. For ongoing concerns, ask your prescriber what condition the medicine treats and what follow-up is planned. Do not stop or take extra tablets based only on symptoms. The right plan depends on your diagnosis and health history.

Sources: FDA26; PT

patient-label-currency — Has the reversal information changed?

Uncertain. Yes. The FDA updated the Eliquis label in June 2026. Its detailed bleeding section no longer names Andexxa. The FDA says US sales ended in December 2025. Other parts of the label still say that a reversal drug is available, so the label is not fully consistent. This does not tell you what treatment is right in an emergency. If serious bleeding happens, call emergency services and tell them you take apixaban. Do not stop treatment or seek a reversal drug by yourself.

Sources: FDA26; FDA-AND

patient-pediatric — Does the adult tablet page apply to children?

Established. No. This page is about adult tablets. Some children with blood clots use separate products: a 0.5 mg tablet in a packet to mix for oral suspension, or 0.15 mg powder in a capsule called ELIQUIS SPRINKLE. The packet or capsule is mixed as the instructions say. Do not swallow the sprinkle capsule. Do not use an adult dose for a child. Ask the child’s pharmacist to show the exact product and steps.

Sources: FDA26

patient-trials — What trials support its uses?

Established. Large studies tested apixaban for different reasons. In ARISTOTLE, stroke or systemic embolism rates were 1.27% per year with apixaban and 1.60% with warfarin. In AMPLIFY, repeat clot or clot-related death happened in 2.3% and 2.7% over six months with apixaban and standard treatment. Those studies involved different people and follow-up periods. The numbers describe groups, not your personal chance. Ask your clinician which evidence matches your diagnosis.

Sources: ARISTOTLE; AMPLIFY; FDA26

Caregiver

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

caregiver-02 — What changes should I look for?

Established. Look for new bruises, nose or gum bleeding, red urine, black stools, or bleeding that will not stop. A fall or hit to the head matters, even if the person seems fine. Write down dose times and any new pills or pain relievers. Call emergency services for heavy bleeding, fainting, sudden weakness, or a bad head injury. Apixaban slows clotting, so bleeding can be harder to stop. Let emergency staff guide what to do about further doses.

Sources: FDA26

caregiver-03 — What is the correct routine?

Established. Adults usually take apixaban tablets twice a day, with or without food. The right dose depends on why it was prescribed, so check the person’s own bottle. Use a written schedule and mark each dose after it is taken. This can help prevent a missed or extra tablet. Do not use someone else’s medicine or an old bottle. If the person has trouble swallowing, ask the pharmacist how to give the medicine safely.

Sources: FDA26

caregiver-05 — What about a missed or duplicated dose?

Established. For a missed adult dose, the label says to take it as soon as possible on the same day and then return to the twice-daily schedule. Do not take two doses at once to catch up. If a dose may have been given twice, call the pharmacist, prescriber, or Poison Help for advice. Write down the time and amount taken. Spanish MedlinePlus uses different missed-dose wording, so do not mix instructions from separate pages. Use the person’s US prescription label and ask a pharmacist if timing is unclear.

Sources: FDA26; PT

caregiver-08 — Can it be split, crushed, or mixed with food?

Established. The adult label says a crushed tablet may be mixed with water, apple juice, or applesauce. It may also be mixed with water and given through a nose-to-stomach tube. Give the mix soon after it is made. A study found that water or tube use gave similar exposure to a whole tablet. Applesauce gave a little less. Child packets and capsules have their own mixing steps. Ask the pharmacist to show the right method and confirm the dose.

Sources: FDA26

caregiver-10 — How should a liquid dose be measured?

Established. Child products are packets or capsules that must be mixed as directed, not a ready-made liquid bottle. A 0.5 mg tablet packet uses 10 mL of water, infant formula, or apple juice. The 0.15 mg ELIQUIS SPRINKLE capsule uses 5 mL of water or infant formula. The dose must be fully mixed and given with an oral syringe. Ask the pharmacist to show the steps from the exact product instructions. Never use a kitchen spoon or baby bottle.

Sources: FDA26

caregiver-14 — Which symptoms require emergency help?

Established. Call 911 for bleeding that will not stop, blood in vomit, black stools, fainting, a sudden bad headache, or new weakness or numbness. Get help after a head injury, even if there is no cut. Tell the team the person takes apixaban and when the last dose was taken. Bleeding can happen inside the body and may not show. Let the team decide what happens to later doses.

Sources: FDA26; FDA-AND

caregiver-17 — What should we record for the next appointment?

Established. Keep a simple record of the dose times, any missed or extra tablet, bruising or bleeding, falls, new medicines, and questions. Bring the medicine bottle or a current list to visits. Note whether the person has kidney or liver problems, a planned procedure, or a change in weight, because these details can affect treatment decisions. Do not use the record to adjust the dose yourself. It helps the care team check whether the prescription and follow-up plan still fit.

Sources: FDA26

caregiver-18 — How should we store and dispose of it?

Established. Keep the adult tablets at room temperature in the labeled bottle or another container the pharmacist approves. Store them away from children and damp places. Child products come in single-use packets or capsules, not a ready-made liquid bottle. Keep those products in their original pack and follow their own storage instructions. Do not share extra medicine or save a prepared mixture. Ask a pharmacist how to return or throw away unused medicine. Check the package for its use-by date.

Sources: FDA26

Pharmacist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

pharmacist-02 — Is the dose appropriate for this patient?

Established. For NVAF, the labeled dose is 5 mg twice daily, reduced to 2.5 mg twice daily when at least two criteria are present: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dL. This rule is indication-specific; acute DVT/PE treatment uses 10 mg twice daily for 7 days then 5 mg twice daily, while extended prevention uses 2.5 mg twice daily after at least 6 months. Do not transfer the NVAF reduction rule to VTE regimens. Check indication, age, weight, renal/hepatic status and interacting drugs.

Sources: FDA26

pharmacist-03 — Which formulation, route, and release type apply?

Established. Adult Eliquis is an immediate-release oral tablet taken twice daily, with or without food. Pediatric forms include 0.5 mg tablets in packets for oral suspension and 0.15 mg powder capsules (ELIQUIS SPRINKLE); both are mixed with product-specific liquids under the Instructions for Use. Crushed adult tablets also have specified administration methods. Do not call the pediatric forms a ready-made oral solution or infer interchangeability of strengths, routes or preparation. Verify the dispensed product, indication, age, weight and administration steps.

Sources: FDA26

pharmacist-04 — What adjustments apply in renal or hepatic impairment?

Established. For NVAF, the US label’s 2.5-mg rule uses at least two of age ≥80 years, weight ≤60 kg, and serum creatinine ≥1.5 mg/dL; it is not a universal renal-function threshold. For moderate hepatic impairment, the label provides no dosing recommendation because of limited clinical experience and intrinsic coagulation abnormalities; severe impairment is not recommended. For VTE regimens, do not apply the NVAF two-of-three rule. Review the indication, organ status and interacting drugs against the relevant label section before confirming a regimen.

Sources: FDA26; DOAC26

pharmacist-05 — What contraindications and allergy concerns matter?

Established. The US label contraindicates apixaban in active pathological bleeding and in patients with severe hypersensitivity to Eliquis or its ingredients. The boxed warnings also cover increased thrombotic risk after premature discontinuation and spinal or epidural hematoma with neuraxial procedures. Use is not recommended in patients with prosthetic heart valves or triple-positive antiphospholipid syndrome; these are not the two formal contraindications. Confirm indication and allergy history, screen for active bleeding, and communicate both boxed warnings before dispensing. Escalate suspected major bleeding for urgent assessment.

Sources: FDA26

pharmacist-06 — Which drug interactions are important?

Established. Combined P-gp and strong CYP3A4 inhibitors raise exposure: reduce the dose by 50% from 5 or 10 mg twice daily; avoid coadministration when the patient already takes 2.5 mg twice daily. Examples include ketoconazole, itraconazole and ritonavir. Combined strong inducers such as rifampin, carbamazepine, phenytoin and St John’s wort can lower exposure and should be avoided. Antiplatelets, NSAIDs and other anticoagulants add bleeding risk through pharmacodynamic effects. Reconcile indication, current dose and the complete medication list before recommending a change.

Sources: FDA26

pharmacist-09 — What baseline and follow-up monitoring is needed?

Established. Routine PT, INR and aPTT are not reliable measures of apixaban effect, and the label does not recommend routine anti-FXa testing to titrate treatment. Clinical follow-up still matters: review bleeding, adherence, kidney and liver function, hemoglobin, indication, dose criteria, interacting drugs and planned procedures. The appropriate interval depends on the patient and current guidance; do not present one fixed schedule as a label mandate. If a serious bleed occurs, follow emergency protocols rather than using a routine laboratory value to decide whether anticoagulation is safe.

Sources: FDA26; DOAC26

pharmacist-11 — What are the missed-dose instructions?

Established. For an adult missed dose, the FDA label says take it as soon as possible on the same day and resume twice-daily dosing; do not double. The Spanish MedlinePlus page uses different wording about skipping when near the next dose, so do not silently combine that translation with the US label. Clarify the exact timing with the patient and use the FDA-approved product directions. For suspected double dosing, direct the patient to the prescriber, pharmacist or Poison Help for individualized advice and document the reported time and amount.

Sources: FDA26; PT

pharmacist-12 — Can this product be crushed or given through a tube?

Established. The adult label permits crushing a tablet and suspending it in water, 5% dextrose in water (D5W), or apple juice, or mixing it with applesauce. For a 12 French nasogastric tube, suspend the tablet in 60 mL water or D5W, give promptly, then flush with 20 mL water or D5W. Pediatric tablets for oral suspension and Sprinkle capsules have separate Instructions for Use. Confirm the product, route, vehicle and order rather than assuming every tube or formulation is interchangeable.

Sources: FDA26

Clinician

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

clinician-01 — Where does this drug fit in treatment?

Established. Apixaban is labeled for stroke/systemic-embolism risk reduction in nonvalvular AF, postoperative DVT prevention after hip or knee replacement, acute DVT/PE treatment, and recurrence reduction after initial VTE therapy. The 2023 AF guideline favors DOACs over warfarin for eligible patients, with important exclusions such as mechanical valves or moderate-to-severe mitral stenosis. For acute PE, consult the 2026 AHA/ACC guideline and current DOAC guidance for recommendation details. This draft does not reproduce specific PE recommendations because full guideline text was not retained here. Match any decision to the labeled indication, patient factors, contraindications and current local recommendations.

Sources: FDA26; AF23; PE26; DOAC26

clinician-04 — How large is the absolute clinical benefit?

Established. In ARISTOTLE, 18,201 patients with AF and stroke-risk factors had annual stroke/systemic-embolism rates of 1.27% with apixaban and 1.60% with warfarin (HR 0.79): 0.33 fewer events per 100 patient-years. Major bleeding was 2.13% versus 3.09% per year. These are annualized rates, not fixed-duration patient risks or a universal NNT. AMPLIFY studied acute VTE over six months and found recurrence/VTE death in 2.3% versus 2.7%. Keep indication, comparator, endpoint and time scale attached to every number.

Sources: ARISTOTLE; AMPLIFY; FDA26

clinician-06 — How applicable is the trial population to my patient?

Established. ARISTOTLE enrolled patients with AF plus at least one additional stroke-risk factor; it does not directly establish benefit for every rhythm disorder or every patient with AF. AMPLIFY excluded, among others, creatinine clearance below 25 mL/min and significant liver disease. Trial exclusions and label populations matter when applying results to severe organ dysfunction, active bleeding, mechanical valves, pregnancy or unusual body size. Compare the patient with the relevant trial and labeled indication, then consult current guidance where evidence or dosing is uncertain.

Sources: ARISTOTLE; AMPLIFY; FDA26; AF23

clinician-07 — What starting dose and titration are labeled?

Established. For NVAF, the labeled regimen is 5 mg twice daily, with 2.5 mg twice daily when at least two of age ≥80 years, weight ≤60 kg and serum creatinine ≥1.5 mg/dL apply. Acute DVT/PE treatment starts with 10 mg twice daily for 7 days then 5 mg twice daily. Extended recurrence prevention uses 2.5 mg twice daily after at least 6 months of treatment; postoperative prophylaxis uses 2.5 mg twice daily. These are separate indication-specific regimens, not a universal titration ladder. Verify renal/hepatic context and interactions.

Sources: FDA26

clinician-10 — What baseline assessment is needed?

Established. Before initiation, confirm the labeled indication, active bleeding status, allergy history, prior thrombotic risk, kidney and hepatic function, weight, pregnancy context and full medication list. For NVAF, document the age, weight and serum-creatinine criteria that determine whether 2.5 mg twice daily applies. Review planned procedures and neuraxial interventions because interruption and catheter timing require a separate plan. The label contraindicates active pathological bleeding and severe hypersensitivity to Eliquis or its ingredients. Assessment should not imply that a normal PT/INR excludes clinically important apixaban activity.

Sources: FDA26

clinician-11 — Which outcomes and tests should be monitored?

Established. Monitor clinical bleeding, thromboembolic symptoms, adherence, hemoglobin, renal and hepatic status, interacting medicines and procedure plans according to the patient’s context. PT, INR and aPTT changes are small and variable, so they do not reliably quantify anticoagulation. The label describes anti-FXa activity as concentration-proportional but does not establish routine dose titration to a laboratory target; §5.2 also says clotting tests or anti-FXa activity are not useful when PCCs are used. Separate follow-up of the patient from laboratory measurement of drug effect.

Sources: FDA26; DOAC26

clinician-15 — Which interactions change management?

Established. Combined P-gp and strong CYP3A4 inhibitors increase apixaban exposure; the label reduces 5- or 10-mg twice-daily regimens by 50% and advises avoiding the combination when the patient is already on 2.5 mg twice daily. Strong combined inducers, including rifampin, carbamazepine and phenytoin, can lower exposure and should be avoided. Antiplatelets, NSAIDs and other anticoagulants increase bleeding through additive pharmacodynamic effects. Review the full regimen and indication before changing therapy; avoid assuming all interaction risks use the same mechanism.

Sources: FDA26

clinician-19 — What changes around surgery, procedures, or illness?

Established. For elective procedures, the label advises stopping at least 48 hours beforehand when bleeding risk is moderate or high, and at least 24 hours for low-risk procedures. These are not universal neuraxial or catheter-removal intervals. The boxed warning describes spinal/epidural hematoma risk, and neuraxial timing needs a procedure-specific plan that considers dose, renal status and catheter management. Premature discontinuation also raises thrombotic risk. Coordinate with the procedural team and follow current specialty guidance rather than applying the general interruption rule to every spinal procedure.

Sources: FDA26; DOAC26

Nurse

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

Safety note. Boxed warnings: early stopping raises clot risk; spinal or epidural hematoma can cause lasting paralysis. Formal contraindications: active pathological bleeding and severe hypersensitivity to Eliquis or its ingredients. FDA26

nurse-02 — What should I check before administration?

Established. Verify patient, indication, tablet strength, dose, and last dose time. For atrial fibrillation, confirm that the chart records the age, weight and serum-creatinine factors used for the 2.5-mg dose rule. Check for active bleeding, allergy, new medicines and planned procedures. Apixaban is usually given twice daily and may be taken with or without food. Do not hold or repeat a dose based only on a routine INR result. If the medication record conflicts with the prescription, clarify before administration.

Sources: FDA26

nurse-03 — Which vital signs and laboratory results matter?

Established. There is no single vital sign or routine clotting test that measures apixaban’s effect. Check for bleeding signs and symptoms, review hemoglobin and kidney or liver results when available, and note weight and new interacting medicines. PT, INR and aPTT changes are small and variable. A normal result does not prove that the drug is absent. Follow unit protocols and the care plan for trends, but do not use an INR target to titrate apixaban as you might for warfarin.

Sources: FDA26

nurse-04 — When should I clarify or hold a dose?

Established. Clarify a dose if the product, indication, strength, schedule or last administration is uncertain, or if active bleeding, a serious allergy, a medication error or an unplanned procedure is reported. Do not create a routine hold rule from feeling well or a normal INR. The label warns that stopping too early raises clot risk. Escalate severe bleeding or a new neurologic symptom urgently. If a procedure is planned, use the prescribed interruption plan and confirm whether neuraxial guidance applies.

Sources: FDA26

nurse-08 — Can this formulation be given through a feeding tube?

Established. The adult label permits a crushed tablet in 60 mL water or D5W through a 12 French nasogastric tube, followed by a 20 mL water or D5W flush. The exposure study used D5W and found results similar to an intact tablet. This does not validate every tube type or pediatric product. Child tablets for oral suspension and Sprinkle capsules have separate Instructions for Use. Check the product and order, and ask pharmacy if the tube route is unclear. Document the dose and flush.

Sources: FDA26

nurse-09 — When should I reassess the patient?

Established. Reassess according to the clinical setting and any change in symptoms, bleeding, procedure status or medication regimen. Apixaban lowers clotting activity, so watch for visible bleeding, blood in urine or stool, unusual bruising, falls and sudden neurologic changes. Check the last dose time and communicate it during handover. There is no label-mandated minute-by-minute reassessment interval for every patient. Use local protocols for acute bleeding or suspected clot, and escalate urgent symptoms promptly rather than waiting for a scheduled check.

Sources: FDA26

nurse-12 — What requires immediate escalation?

Established. Escalate severe or uncontrolled bleeding, vomiting blood, black stools, red or brown urine, fainting, a serious fall or head injury, and new weakness, numbness or severe back pain after a spinal procedure. These may signal bleeding that needs urgent assessment. Tell the treating team that the patient takes apixaban and when the last dose was given. Do not use the older DailyMed named-agent wording to promise a reversal drug is available in the United States. Follow emergency protocols and current local direction.

Sources: FDA26; FDA-AND

nurse-14 — What if a dose is missed, refused, or vomited?

Established. For an adult missed dose, the label says to take it as soon as possible on the same day and then resume twice-daily dosing; do not double. If a dose is refused, document and notify the care team rather than hiding it in food without approval. For vomiting after a dose, the label does not give a universal repeat-dose rule, so clarify with the pharmacist or prescriber. Record the time, amount and symptoms. Separate missed-dose instructions from advice for a possible overdose.

Sources: FDA26; PT

nurse-18 — What should teach-back check?

Established. Ask the patient to explain why they take apixaban, when they take each dose, and what they would do after a missed dose or serious bleed. Check that they understand not to stop treatment without a clinician-directed plan. Ask them to name medicines such as ibuprofen or aspirin that need review and to tell procedural teams before surgery or spinal procedures. Have them show how they will keep a dose record. Correct misunderstandings before discharge and give the current product-specific written instructions.

Sources: FDA26

Student

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

student-03 — What is the mechanism of action?

Established. Apixaban is an oral, direct factor Xa inhibitor. Xa combines with factor Va, calcium and a phospholipid surface in the prothrombinase complex to convert prothrombin into thrombin. Apixaban inhibits free and clot-bound Xa without requiring antithrombin, reducing thrombin generation and fibrin formation. Less thrombin also means less thrombin-driven platelet activation downstream, although the label says apixaban has no direct platelet effect. This is anticoagulation, not fibrinolysis: it limits clot formation rather than dissolving an existing clot.

Sources: FDA26

student-05 — How is it absorbed, distributed, metabolized, and eliminated?

Established. The label reports about 50% oral bioavailability, peak concentration in 3–4 hours, and about 87% protein binding. CYP3A4 is the main metabolic route, with smaller contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2. About 25% of an oral dose is recovered in urine and feces as metabolites; renal excretion accounts for about 27% of total clearance. Biliary and direct intestinal excretion also contribute. Do not equate renal clearance with unchanged drug excretion.

Sources: FDA26

student-07 — What does its half-life mean clinically?

Established. The label gives an apparent half-life of about 12 hours in adults. That supports twice-daily administration, but half-life alone does not determine an individual dose or guarantee a fixed offset time. Apixaban exposure also depends on absorption, kidney and liver function, age, interacting drugs and dose. Its anticoagulant effect may persist for at least 24 hours after the last dose, about two half-lives, according to the June 2026 label. Procedure timing therefore needs a risk-specific plan rather than simple arithmetic.

Sources: FDA26

student-09 — What are the key adverse effects?

Established. Bleeding is the central serious adverse effect because inhibiting factor Xa lowers thrombin generation needed for clot formation. The FDA boxed warning also covers increased thrombotic events after premature discontinuation and spinal or epidural hematoma that can cause permanent paralysis. Active pathological bleeding and severe hypersensitivity to Eliquis or its ingredients are contraindications. Separate expected mechanism from observed event rates: ARISTOTLE reported major bleeding at 2.13% per year with apixaban versus 3.09% with warfarin in its AF population, but that rate cannot be applied to every indication.

Sources: FDA26; ARISTOTLE

student-12 — Which interactions matter most?

Established. Combined P-gp and strong CYP3A4 inhibitors can raise apixaban exposure, so the US label halves 5- or 10-mg twice-daily doses and avoids the combination at 2.5 mg twice daily. Combined strong inducers can lower exposure and should be avoided. Aspirin, NSAIDs and other anticoagulants can increase bleeding through additive effects, even without changing apixaban concentration. This illustrates pharmacokinetic versus pharmacodynamic interaction. Use the exact labeled interaction rule and do not treat every interacting medicine as a dose-reduction case.

Sources: FDA26

student-13 — What monitoring is needed, and why?

Established. Clinical monitoring looks for bleeding, new clots, adherence problems, renal or hepatic change and new interacting medicines. Routine PT, INR and aPTT are not reliable measures of apixaban effect because changes are small and variable. Anti-FXa activity can track concentration in pharmacodynamic studies, but the label does not make it a routine titration target. When prothrombin complex concentrates are used, the June 2026 label says clotting tests or anti-FXa testing are not useful or recommended for monitoring.

Sources: FDA26; DOAC26

student-18 — What are the principles of overdose management?

Established. Overdose can cause bleeding. The June 2026 label says activated charcoal may reduce absorption after ingestion; in healthy subjects, charcoal given 2 or 6 hours after 20 mg reduced mean exposure by 50% and 27%. It also says PCC, activated PCC or recombinant factor VIIa may be considered but have not been evaluated in clinical studies. The label has inconsistent generic reversal language, and Andexxa sales ended in the United States. Treatment decisions belong to emergency and toxicology teams, not self-care.

Sources: FDA26; FDA-AND

student-19 — What evidence established its clinical role?

Established. Separate trials support different indications. ARISTOTLE compared apixaban with warfarin in atrial fibrillation; AVERROES studied patients unsuitable for warfarin versus aspirin; AMPLIFY tested acute VTE treatment; AMPLIFY-EXT studied extended prevention after initial therapy; ADVANCE trials studied postsurgical prevention. Their endpoints and follow-up differ. For example, ARISTOTLE’s event rates are annualized, while AMPLIFY reports proportions over six months. Do not pool the results or call one number the medicine’s universal benefit.

Sources: ARISTOTLE; AVERROES; AMPLIFY; AMPLIFY-EXT; ADVANCE

Scientist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

scientist-01 — What is the primary target and its evidence base?

Established. The primary molecular target is human factor Xa, a serine protease in the prothrombinase complex. The US label states that apixaban directly inhibits free and clot-bound Xa and prothrombinase activity without requiring antithrombin. Wong et al. report a human FXa Ki of 0.08 nM in an in-vitro assay. The crystallographic record 2P16 places apixaban in a human FXa construct at 2.30 Å resolution. These biochemical and structural observations support target binding, while clinical efficacy requires separate outcome evidence.

Sources: FDA26; WONG; 2P16

scientist-02 — Is the proposed mechanism causal or associated?

Established. The causal pharmacology is supported by direct enzyme inhibition: apixaban binds and inhibits FXa, reducing prothrombinase-mediated thrombin generation. The label also reports concentration-related anti-FXa activity and reduced thrombin generation. Randomized trials show clinical outcomes in defined populations, but they do not isolate every downstream mediator. Thus, direct target inhibition is established pharmacology, while the contribution of each cellular or coagulation feedback pathway to a patient’s outcome is not separately quantified by the trial abstracts. Keep target, biomarker and outcome evidence as distinct layers.

Sources: FDA26; WONG; ARISTOTLE

scientist-03 — How can target engagement be measured?

Established. In vitro, quantify FXa catalytic activity across apixaban concentrations and report assay conditions, substrate and free-drug assumptions. In vivo, the label describes a concentration-related anti-FXa chromogenic assay signal and reduced thrombin-generation measures. These are pharmacodynamic readouts, not validated routine dose targets for every patient. PT, INR and aPTT are small and variable. In reversal settings involving PCC, the June label says clotting tests or anti-FXa activity are not useful or recommended for monitoring. Pair any biomarker with exposure and clinical endpoints.

Sources: FDA26; WONG

scientist-06 — What tissue exposures are known?

Established. The retrieved label and trial abstracts do not provide quantitative apixaban concentrations in human tissues such as liver, kidney, lung or clot. Plasma pharmacokinetics are better characterized: about 87% protein binding, a 3–4-hour time to peak, and a roughly 12-hour apparent half-life. PDB 2P16 is an isolated protein–ligand structure, not a tissue-distribution study. Tissue exposure would require validated sampling or imaging with a defined assay and population; do not infer it from plasma exposure or the crystal structure.

Sources: FDA26; 2P16

scientist-07 — Are experimental concentrations clinically plausible?

Established. Wong et al. report potent FXa inhibition in vitro, with a human FXa Ki of 0.08 nM, while the label gives plasma exposure and about 87% protein binding. Comparing assay concentrations with clinical exposure requires matching unbound concentration, matrix, protein binding, substrate conditions and timing. A nominal in-vitro concentration cannot be equated directly with total plasma concentration. Use the source-specific assay conditions and report free-drug assumptions; the retained abstract alone does not establish a full clinical exposure-response threshold.

Sources: WONG; FDA26

scientist-08 — Which metabolites contribute to activity or toxicity?

Established. The label says about 25% of an oral dose is recovered in urine and feces as metabolites. It names CYP3A4 as the main metabolic route and O-demethylation and hydroxylation as major transformation sites. It also says unchanged apixaban is the major drug-related component in plasma and that there are no active circulating metabolites. These facts do not establish the activity of every excreted metabolite or its contribution to toxicity. Keep metabolite abundance and functional activity separate.

Sources: FDA26

scientist-15 — Which biomarkers track engagement or response?

Established. Anti-FXa activity is concentration-related in the label, and thrombin-generation assays provide a downstream pharmacodynamic readout. Neither should be conflated with routine clinical monitoring or an established universal target range. PT, INR and aPTT are small and variable. The label specifically cautions that clotting tests and anti-FXa activity are not useful for monitoring when PCCs are used. Clinical response is indication-specific, so link biomarkers to exposure and outcomes in the relevant population rather than using a laboratory signal as a surrogate for benefit.

Sources: FDA26

scientist-20 — Which next experiment would reduce uncertainty?

Probable. A useful next experiment would prospectively link free apixaban exposure, FXa inhibition and thrombin-generation response in a defined population with altered renal function or interacting medicines. Prespecify sampling times, assay matrix, calibration, concomitant drugs and clinical bleeding or clot outcomes. This would test exposure–response rather than assume that one anti-FXa value predicts benefit. The design should distinguish target engagement from clinical outcome and should not claim a universal therapeutic range unless independently validated. Current sources establish pharmacology but do not supply that complete model.

Sources: FDA26; DOAC26

Chemist

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

chemist-01 — What is the structure and active molecular form?

Established. Apixaban is a small-molecule, orally active direct factor Xa inhibitor with molecular weight about 459.5. The marketed Eliquis active ingredient is apixaban, not a prodrug that requires conversion to an active metabolite. The FDA label describes negligible ionization across pH 1.2–6.8, low aqueous solubility and approximately 50% absolute bioavailability. The 2P16 X-ray structure shows the ligand in a human FXa construct at 2.30 Å. The coordinate record supports a binding-site view, not a complete solution structure.

Sources: FDA26; 2P16

chemist-02 — Which functional groups matter for activity?

Uncertain. The label and retained 2P16 record establish a small-molecule ligand bound in the factor Xa active site, while Pinto et al. identify apixaban as compound 40 in a discovery series. The present source bundle does not include the full paper figures needed to verify residue-by-residue S1/S4 contacts or a single-group causal SAR narrative. Describe the scaffold and structure as observed, but mark detailed interaction assignments for figure-level confirmation. Avoid saying one methoxy group alone created oral activity; absorption reflects the whole molecule and formulation.

Sources: PINTO; 2P16; FDA26

chemist-05 — What supports the proposed binding mode?

Established. RCSB PDB entry 2P16 is an experimental X-ray structure of apixaban bound to human factor Xa at 2.30 Å resolution. It supports occupancy of the enzyme binding pocket in the crystallized construct. It does not show intact prothrombinase, a dynamic binding pathway, in-vivo occupancy or clinical selectivity. The label independently states direct inhibition of free and clot-bound Xa. Specific residue contacts and S1/S4 assignments should be checked against the coordinates or full structural paper before they are described as established.

Sources: 2P16; FDA26

chemist-06 — Is target binding reversible or irreversible?

Established. The label describes apixaban as a direct, reversible inhibitor of factor Xa. Its effect declines as drug concentration falls, with an apparent half-life of about 12 hours in adults, but recovery is not a fixed timer for an individual. The June 2026 label says effects may persist at least 24 hours after the last dose. That pharmacokinetic description should not be used alone to set neuraxial or procedural intervals. Distinguish reversible binding at the target from the clinical time course of anticoagulation.

Sources: FDA26

chemist-07 — How do ionization and pKa affect behavior?

Established. The FDA label reports apixaban is non-ionized over pH 1.2–6.8 and has low solubility in water. These properties are relevant to dissolution and absorption, but the retrieved label does not provide a numeric pKa. Do not invent one from a database estimate or infer that lack of ionization guarantees absorption. The drug’s absolute bioavailability is about 50%, and absorption can become dissolution-limited at doses of 25 mg or more. A numeric pKa claim needs a primary measurement with defined conditions.

Sources: FDA26

chemist-08 — What is known about solubility and dissolution?

Established. The FDA label gives an aqueous solubility of about 0.04 mg/mL across pH 1.2–6.8 and says absorption becomes dissolution-limited at doses of 25 mg or more. Absolute oral bioavailability is about 50%, and food does not affect it at labeled doses. Crushed tablets mixed with applesauce lowered peak concentration and total exposure by 20% and 16%; water suspension or nasogastric delivery gave similar exposure to intact tablets in the reported studies. These findings are product-specific, not a general rule for other formulations.

Sources: FDA26

chemist-10 — Which transporters influence disposition?

Established. Apixaban is a substrate of P-glycoprotein and BCRP according to the label. P-gp is also part of the combined interaction rule with strong CYP3A4 inhibitors or inducers, which can change exposure. Transporter substrate status does not mean apixaban is a transporter inhibitor at therapeutic concentrations or that transporter expression alone predicts patient response. The retrieved evidence supports the label’s interaction framework; any quantitative contribution of an individual transporter to clinical variability needs a dedicated study and should be separated from CYP metabolism.

Sources: FDA26

chemist-11 — What are the main metabolic pathways?

Established. The label identifies CYP3A4 as the main metabolic route, with smaller contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2. It lists O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety as major transformation sites. About 25% of an oral dose is recovered in urine and feces as metabolites, while unchanged apixaban is the main drug-related component in plasma. Apixaban is also a P-gp and BCRP substrate. Do not assign pathway fractions without supporting data.

Sources: FDA26

Investor / Diligence Analyst

Questions for this perspective

8 drafted questions in this packet. Targeted additions or replacements for the current guide.

analyst-03 — How large is the reachable patient market?

Established. CMS reports 3.928 million Medicare Part D enrollees used Eliquis in its specified 2023 measurement period, with $18.275 billion in gross covered Part D drug costs. These are utilization and gross-cost signals, not unique worldwide patients, eligible untreated demand, manufacturer revenue or a current market forecast. The 2026 negotiated maximum fair price is $231 per 30-day supply versus a $521 list-price reference, a 56% reduction under the program. A market model still needs indication, geography, payer, net price and switching assumptions.

Sources: CMS26

analyst-06 — How strong is the human efficacy evidence?

Established. Randomized evidence spans distinct settings. ARISTOTLE enrolled 18,201 patients with AF and additional stroke risk; stroke/systemic embolism was 1.27% versus 1.60% per year against warfarin, HR 0.79. AMPLIFY enrolled acute VTE patients and found recurrent VTE or VTE-related death in 2.3% versus 2.7% over six months against enoxaparin/warfarin. AVERROES and postoperative ADVANCE trials answer different questions. The outcome package is substantial, but each result must remain tied to its population, comparator, endpoint and follow-up.

Sources: ARISTOTLE; AMPLIFY; AVERROES; ADVANCE; FDA26

analyst-07 — Is the demonstrated benefit clinically meaningful?

Established. Meaning depends on indication and comparator. In ARISTOTLE, the absolute annual difference in stroke/systemic embolism was 0.33 percentage points and major bleeding was 0.96 points lower per year versus warfarin. These annualized rates are not a fixed-duration NNT and should not be transferred to VTE treatment or surgery prevention. AMPLIFY’s six-month recurrence difference was smaller and its confidence interval included no difference, while major bleeding was lower. Diligence should preserve endpoint definitions, time horizons and uncertainty instead of presenting one universal benefit figure.

Sources: ARISTOTLE; AMPLIFY

analyst-08 — How credible are the trial design and endpoints?

Established. ARISTOTLE was a randomized active-comparator trial with 18,201 participants and median 1.8-year follow-up; its annualized stroke/systemic-embolism endpoint differs from AMPLIFY’s six-month recurrent-VTE composite. ADVANCE trials used postoperative composites and different enoxaparin regimens; ADVANCE-1 did not meet its noninferiority criterion. These differences make pooled headline rates misleading. Review full protocols and reports for adjudication, missing data, subgroup definitions, multiplicity and generalizability. Abstracts support a high-level map, not a complete assessment of bias or endpoint sensitivity.

Sources: ARISTOTLE; AMPLIFY; ADVANCE

analyst-12 — What are the next decisive development milestones?

Uncertain. For an established branded anticoagulant, a diligence plan should first define the proposed opportunity: indication, population, geography, formulation and evidence gap. Relevant milestones may include a current label and competition review, payer evidence, supply validation, and a protocol or regulatory discussion for any new claim. The retained sources do not identify a new sponsor program, trial design or commercial launch plan. Do not invent a budget or date. Ask for a target product profile, decision criteria, named owner and go/no-go evidence before forecasting milestones.

Sources: FDA26; DOAC26

analyst-15 — What capital and time would the next milestone require?

Uncertain. A defensible estimate depends on whether the plan is generic entry, a new formulation, new indication, evidence generation or commercialization. The existing trial record does not supply a current sponsor budget, vendor plan or development timeline. Build an estimate from a defined protocol, sample size, manufacturing and quality scope, regulatory pathway, geography and payer evidence needs. State assumptions and contingencies. Without those inputs, a dollar figure or launch date would be invented rather than supported by the retained public evidence.

Sources: FDA26; DOAC26

analyst-16 — What patents, exclusivity, and freedom-to-operate issues apply?

Probable. Pfizer’s 2025 Form 10-K describes a settlement path for licensed US generic apixaban entry on April 1, 2028, subject to earlier litigation outcomes. Treat that as a conditional agreement date, not a guaranteed earliest entry date. A complete diligence review still needs current Orange Book listings, patent claims, settlement terms, regulatory status and jurisdiction-specific counsel. Generic-entry timing does not establish freedom to operate for a new formulation, combination or indication. Keep the public date separate from legal conclusions.

Sources: SEC25; FDA-APP

analyst-18 — What would support reimbursement and pricing?

Established. CMS’s 2026 negotiated maximum fair price is a program-specific $231 per 30-day supply, compared with a $521 list-price reference and a reported 56% reduction. It is not a patient’s pharmacy quote, a net manufacturer price or a price available to every payer. For reimbursement diligence, confirm the eligible population, formulary placement, out-of-pocket exposure, adherence impact and competing anticoagulants by market. Record date, strength, quantity and channel for every quote. The Medicare utilization data should not be treated as evidence of commercial adoption alone.

Sources: CMS26

[FOUNDER TO SUPPLY: qualified independent anticoagulation, neuraxial, bleeding/reversal and patient-copy review.] [VERIFY: numeric pKa source and measurement conditions; quantitative human tissue concentrations; full 2026 guideline recommendation wording; current payer formularies, net prices and adoption evidence; defined sponsor, program, milestones, capital plan and timeline. Verify current label, jurisdictional policy and commercial dates before release.] Emergency reversal choices and patient-specific interruption or dose changes require the treating team.

General

Questions for this perspective

This packet does not replace the existing questions for this perspective. Use the current guide for those answers; the expanded explanation above is new.